成人異常ヘモグロビン症検査の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

世界の成人異常ヘモグロビン症検査の市場規模は、2025年に3億8,210万米ドルになるとみられ、2025年～2032年の予測期間に4.4%のCAGRで拡大し、2032年には5億4,040万米ドルに達すると予測されています。

成人異常ヘモグロビン症検査は、鎌状赤血球症やサラセミアなどの血液疾患の診断とモニタリングにおいて重要な役割を果たしています。この市場には、ヘモグロビン電気泳動、高速液体クロマトグラフィー（HPLC）、分子診断など、さまざまな検査技術が含まれ、病院、診療所、診断研究所、調査現場向けに診断ソリューションを提供しています。市場成長の原動力は、ヘモグロビン異常症に対する世界の認知度の高まり、診断技術を支援する政府・民間セクターの取り組みの活発化、より迅速で正確な結果を提供する検査法の進歩です。

世界の成人異常ヘモグロビン症検査市場は、特に鎌状赤血球症などの遺伝性疾患が蔓延しているアフリカ、中東、アジア太平洋などの地域におけるヘモグロビン異常症の有病率の上昇など、いくつかの重要な要因によって推進されています。ヘルスケアに対する意識の高まり、ヘルスケアサービスへのアクセスの改善、研究投資の増加が検査ソリューションの需要拡大に寄与しています。自動検査システムや非侵襲的検査法の開発などの技術的進歩は、検査精度とアクセシビリティを向上させ、市場の成長を促進しています。さらに、ヘモグロビン異常症のスクリーニングプログラムや新生児スクリーニングの取り組みが増加していることも、市場の普及を後押ししています。

成人異常ヘモグロビン症検査市場は、技術革新、人口動向、世界のヘルスケア構想によって大きな成長機会がもたらされます。費用対効果が高く、携帯可能で使い勝手の良い診断機器の開発により、検査へのアクセス性が向上し、検査範囲が拡大する新たな機会が生まれています。さらに、症状が現れる前にヘモグロビン異常症を特定するための分子診断や遺伝子検査の利用拡大が需要を牽引しています。このような機会を生かすためには、業界各社とヘルスケアプロバイダーとの戦略的提携や、検査法を強化するための研究開発への投資が不可欠です。

当レポートでは、世界の成人異常ヘモグロビン症検査市場について調査し、異型タイプ別、検査タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 成人異常ヘモグロビン症検査市場機会分析

第4章 市場背景

第5章 北米の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

第6章 ラテンアメリカの成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

第7章 欧州の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

第8章 日本を除くアジア太平洋の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

第9章 日本の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

第10章 中東・アフリカの成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

第11章 予測の前提条件

第12章 競合分析

• 競合ダッシュボード
• 企業の詳細
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • Chromsystems Instruments & Chemicals GmbH
  • BioMedomics, Inc
  • CapitalBio Technology Inc
  • Trinity Biotech
  • Streck, Inc.

第13章 世界の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）、地域別

第14章 世界の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）、異型タイプ別

第15章 世界の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）、検査タイプ別

第16章 世界の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）、エンドユーザー別

第17章 世界の成人異常ヘモグロビン症検査市場分析（2019年～2024年）および予測（2025年～2032年）

Persistence Market Research has recently released a comprehensive report on the worldwide market for adult hemoglobinopathy testing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global adult hemoglobinopathy testing market from 2025 to 2032.

Key Insights:

• Adult Hemoglobinopathy Testing Market Size (2025E): USD 382.1 Mn
• Projected Market Value (2032F): USD 540.4 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 4.4%

Adult Hemoglobinopathy Testing Market - Report Scope:

Adult hemoglobinopathy testing plays a critical role in the diagnosis and monitoring of blood disorders, such as sickle cell disease and thalassemia. The market includes a variety of testing technologies, including hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and molecular diagnostics, offering diagnostic solutions for hospitals, clinics, diagnostic laboratories, and research settings. The market growth is driven by rising global awareness of hemoglobinopathies, increased government and private sector initiatives to support diagnostic technologies, and advancements in testing methods that provide faster and more accurate results.

Market Growth Drivers:

The global adult hemoglobinopathy testing market is propelled by several key factors, including an increasing prevalence of hemoglobinopathies, particularly in regions like Africa, the Middle East, and Asia Pacific, where genetic disorders such as sickle cell disease are widespread. Rising healthcare awareness, improved access to healthcare services, and growing research investments are contributing to the growing demand for testing solutions. Technological advancements, such as the development of automated testing systems and non-invasive testing methods, are enhancing testing accuracy and accessibility, thus fostering market growth. Moreover, the increasing number of screening programs and newborn screening initiatives for hemoglobinopathies are boosting market adoption.

Market Restraints:

Despite the promising growth prospects, the adult hemoglobinopathy testing market faces challenges related to high testing costs, limited access to advanced diagnostic tools in low-income regions, and the lack of standardized testing protocols across different countries. Additionally, limited reimbursement coverage for certain diagnostic tests and the complexity of some testing methods could restrict market growth, particularly in resource-constrained settings. These challenges require the development of affordable, accessible, and standardized testing solutions to expand the market reach and ensure effective disease management.

Market Opportunities:

The adult hemoglobinopathy testing market presents significant growth opportunities driven by technological innovations, demographic trends, and global healthcare initiatives. The development of more cost-effective, portable, and user-friendly diagnostic devices is creating new opportunities to improve accessibility and expand testing reach. Furthermore, the expanding use of molecular diagnostics and genetic testing to identify hemoglobinopathies before symptoms appear is driving demand. Strategic collaborations between industry players and healthcare providers, as well as investments in research and development to enhance testing methods, will be crucial for capitalizing on these opportunities.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the adult hemoglobinopathy testing market globally?
• Which testing technologies are most widely used in the diagnosis of hemoglobinopathies, and how are they evolving?
• How are advancements in diagnostic technologies reshaping the competitive landscape of the adult hemoglobinopathy testing market?
• Who are the key players contributing to the adult hemoglobinopathy testing market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global adult hemoglobinopathy testing market?

Competitive Intelligence and Business Strategy:

Leading players in the global adult hemoglobinopathy testing market, such as Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, and Beckman Coulter, Inc., focus on product innovation, strategic partnerships, and expanding their market reach. These companies invest in R&D to develop advanced testing solutions, including automated and portable diagnostic systems, to cater to diverse patient needs and healthcare settings. Collaborations with hospitals, diagnostic laboratories, and healthcare organizations help facilitate market access and enhance technology adoption. Furthermore, companies are increasingly focusing on regional expansion, particularly in emerging markets, to capture a larger share of the market.

Key Companies Profiled:

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific
• Beckman Coulter, Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Sebia S.A.
• Ortho Clinical Diagnostics
• Siemens Healthineers
• HemoTypeS
• Helena Laboratories Corporation

The Adult Hemoglobinopathy Testing Market is Segmented Based on:

Variant Type

• Variant A2
• Variant F

Test Type

• HPLC Test
• Mass Spectrometry
• Hb electrophoresis

End Users

• Hospitals
• Reference Laboratories
• Academic & Medical institutes

Region

• North America
• Latin America
• Europe
• Asia Pacific
• Japan
• Japan and Middle-East
• Africa

Table of Contents

1. Executive Summary

• 1.1. Market Overview
• 1.2. Market Analysis
• 1.3. PMR Analysis and Recommendations
• 1.4. Wheel of Fortune

2. Market Introduction

• 2.1. Market Definition
• 2.2. Market Taxonomy

3. Adult Hemoglobinopathy Testing Market Opportunity Analysis

• 3.1. Macro-Economic Factors
• 3.2. Opportunity Analysis

4. Market Background

• 4.1. Market Dynamics
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Trends
• 4.2. Reimbursement Scenario
• 4.3. Regional Pricing Analysis by Test Type (2024)
• 4.4. Disease Epidemiology (2024)

5. North America Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 5.1. Introduction
• 5.2. Historical Market Size (US$ Mn) Analysis By Country, 2019 - 2024
  • 5.2.1. U.S.
  • 5.2.2. Canada
• 5.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
• 5.4. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 5.4.1. Hemoglobin F
  • 5.4.2. Hemoglobin A2
• 5.5. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 5.6. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 5.6.1. HPLC Test
  • 5.6.2. Hb Electrophoresis
  • 5.6.3. Mass Spectrometry
• 5.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 5.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 5.8.1. Reference Laboratories
  • 5.8.2. Hospitals
  • 5.8.3. Academic and Medical Institutes
• 5.9. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 5.10. Market Attractiveness Analysis
  • 5.10.1. By Country
  • 5.10.2. By Variant Type
  • 5.10.3. By Test Type
  • 5.10.4. By End User
• 5.11. Drivers and Restraints - Impact Analysis

6. Latin America Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 6.1. Introduction
• 6.2. Historical Market Size (US$ Mn) Trends Analysis By Country, 2019 - 2024
  • 6.2.1. Brazil
  • 6.2.2. Mexico
  • 6.2.3. Rest of Latin America
• 6.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
• 6.4. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 6.4.1. Hemoglobin F
  • 6.4.2. Hemoglobin A2
• 6.5. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 6.6. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 6.6.1. HPLC Test
  • 6.6.2. Hb Electrophoresis
  • 6.6.3. Mass Spectrometry
• 6.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 6.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 6.8.1. Reference Laboratories
  • 6.8.2. Hospitals
  • 6.8.3. Academic and Medical Institutes
• 6.9. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 6.10. Market Attractiveness Analysis
  • 6.10.1. By Country
  • 6.10.2. By Variant Type
  • 6.10.3. By Test Type
  • 6.10.4. By End User
• 6.11. Drivers and Restraints - Impact Analysis

7. Europe Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 7.1. Introduction
• 7.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019 - 2024
  • 7.2.1. Germany
  • 7.2.2. U.K.
  • 7.2.3. France
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Rest of Europe
• 7.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
• 7.4. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 7.4.1. Hemoglobin F
  • 7.4.2. Hemoglobin A2
• 7.5. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 7.6. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 7.6.1. HPLC Test
  • 7.6.2. Hb Electrophoresis
  • 7.6.3. Mass Spectrometry
• 7.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 7.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 7.8.1. Reference Laboratories
  • 7.8.2. Hospitals
  • 7.8.3. Academic and Medical Institutes
• 7.9. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 7.10. Market Attractiveness Analysis
  • 7.10.1. By Country
  • 7.10.2. By Variant Type
  • 7.10.3. By Test Type
  • 7.10.4. By End User
• 7.11. Drivers and Restraints - Impact Analysis

8. Asia Pacific Excluding Japan Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 8.1. Introduction
• 8.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019 - 2024
  • 8.2.1. China
  • 8.2.2. India
  • 8.2.3. Australia and New Zealand
  • 8.2.4. Rest of Asia Pacific
• 8.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
• 8.4. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 8.4.1. Hemoglobin F
  • 8.4.2. Hemoglobin A2
• 8.5. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 8.6. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 8.6.1. HPLC Test
  • 8.6.2. Hb Electrophoresis
  • 8.6.3. Mass Spectrometry
• 8.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 8.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 8.8.1. Reference Laboratories
  • 8.8.2. Hospitals
  • 8.8.3. Academic and Medical Institutes
• 8.9. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 8.10. Market Attractiveness Analysis
  • 8.10.1. By Country
  • 8.10.2. By Variant Type
  • 8.10.3. By Test Type
  • 8.10.4. By End User
• 8.11. Drivers and Restraints - Impact Analysis

9. Japan Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 9.1. Introduction
• 9.2. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 9.2.1. Hemoglobin F
  • 9.2.2. Hemoglobin A2
• 9.3. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 9.4. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 9.4.1. HPLC Test
  • 9.4.2. Hb Electrophoresis
  • 9.4.3. Mass Spectrometry
• 9.5. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 9.6. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 9.6.1. Reference Laboratories
  • 9.6.2. Hospitals
  • 9.6.3. Academic and Medical Institutes
• 9.7. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 9.8. Market Attractiveness Analysis
  • 9.8.1. By Variant Type
  • 9.8.2. By Test Type
  • 9.8.3. By End User
• 9.9. Drivers and Restraints - Impact Analysis

10. Middle East & Africa Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2019 - 2024
  • 10.2.1. GCC Countries
  • 10.2.2. South Africa
  • 10.2.3. Rest of MEA
• 10.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
• 10.4. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 10.4.1. Hemoglobin F
  • 10.4.2. Hemoglobin A2
• 10.5. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 10.6. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 10.6.1. HPLC Test
  • 10.6.2. Hb Electrophoresis
  • 10.6.3. Mass Spectrometry
• 10.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 10.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 10.8.1. Reference Laboratories
  • 10.8.2. Hospitals
  • 10.8.3. Academic and Medical Institutes
• 10.9. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 10.10. Market Attractiveness Analysis
  • 10.10.1. By Country
  • 10.10.2. By Variant Type
  • 10.10.3. By Test Type
  • 10.10.4. By End User
• 10.11. Drivers and Restraints - Impact Analysis

11. Forecast Assumptions

12. Competition Analysis

• 12.1. Competition Dashboard
• 12.2. Company Deep Dive
  • 12.2.1. Bio-Rad Laboratories, Inc.
    • 12.2.1.1. Overview
    • 12.2.1.2. Product and Application Portfolio
    • 12.2.1.3. Production Footprint
    • 12.2.1.4. Sales Footprint
    • 12.2.1.5. Channel Footprint
    • 12.2.1.6. Strategy
      • 12.2.1.6.1. Marketing Strategy
      • 12.2.1.6.2. Product Strategy
      • 12.2.1.6.3. Channel Strategy
  • 12.2.2. Thermo Fisher Scientific Inc.
    • 12.2.2.1. Overview
    • 12.2.2.2. Product and Application Portfolio
    • 12.2.2.3. Production Footprint
    • 12.2.2.4. Sales Footprint
    • 12.2.2.5. Channel Footprint
    • 12.2.2.6. Strategy
      • 12.2.2.6.1. Marketing Strategy
      • 12.2.2.6.2. Product Strategy
      • 12.2.2.6.3. Channel Strategy
  • 12.2.3. PerkinElmer Inc.
    • 12.2.3.1. Overview
    • 12.2.3.2. Product and Application Portfolio
    • 12.2.3.3. Production Footprint
    • 12.2.3.4. Sales Footprint
    • 12.2.3.5. Channel Footprint
    • 12.2.3.6. Strategy
      • 12.2.3.6.1. Marketing Strategy
      • 12.2.3.6.2. Product Strategy
      • 12.2.3.6.3. Channel Strategy
  • 12.2.4. Chromsystems Instruments & Chemicals GmbH
    • 12.2.4.1. Overview
    • 12.2.4.2. Product and Application Portfolio
    • 12.2.4.3. Production Footprint
    • 12.2.4.4. Sales Footprint
    • 12.2.4.5. Channel Footprint
    • 12.2.4.6. Strategy
      • 12.2.4.6.1. Marketing Strategy
      • 12.2.4.6.2. Product Strategy
      • 12.2.4.6.3. Channel Strategy
  • 12.2.5. BioMedomics, Inc
    • 12.2.5.1. Overview
    • 12.2.5.2. Product and Application Portfolio
    • 12.2.5.3. Production Footprint
    • 12.2.5.4. Sales Footprint
    • 12.2.5.5. Channel Footprint
    • 12.2.5.6. Strategy
      • 12.2.5.6.1. Marketing Strategy
      • 12.2.5.6.2. Product Strategy
      • 12.2.5.6.3. Channel Strategy
  • 12.2.6. CapitalBio Technology Inc
    • 12.2.6.1. Overview
    • 12.2.6.2. Product and Application Portfolio
    • 12.2.6.3. Production Footprint
    • 12.2.6.4. Sales Footprint
    • 12.2.6.5. Channel Footprint
    • 12.2.6.6. Strategy
      • 12.2.6.6.1. Marketing Strategy
      • 12.2.6.6.2. Product Strategy
      • 12.2.6.6.3. Channel Strategy
  • 12.2.7. Trinity Biotech
    • 12.2.7.1. Overview
    • 12.2.7.2. Product and Application Portfolio
    • 12.2.7.3. Production Footprint
    • 12.2.7.4. Sales Footprint
    • 12.2.7.5. Channel Footprint
    • 12.2.7.6. Strategy
      • 12.2.7.6.1. Marketing Strategy
      • 12.2.7.6.2. Product Strategy
      • 12.2.7.6.3. Channel Strategy
  • 12.2.8. Streck, Inc .
    • 12.2.8.1. Overview
    • 12.2.8.2. Product and Application Portfolio
    • 12.2.8.3. Production Footprint
    • 12.2.8.4. Sales Footprint
    • 12.2.8.5. Channel Footprint
    • 12.2.8.6. Strategy
      • 12.2.8.6.1. Marketing Strategy
      • 12.2.8.6.2. Product Strategy
      • 12.2.8.6.3. Channel Strategy

13. Global Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

• 13.1. Introduction/Key Findings
• 13.2. Historical Market Size (US$ Mn) Analysis By Region, 2019 - 2024
• 13.3. Market Size (US$ Mn) Forecast By Region, 2025 - 2032
  • 13.3.1. North America
  • 13.3.2. Latin America
  • 13.3.3. Europe
  • 13.3.4. Asia Pacific
  • 13.3.5. Middle East & Africa
• 13.4. Market Attractiveness Analysis By Region

14. Global Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Variant Type

• 14.1. Introduction/Key Findings
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Variant Type, 2019 - 2024
  • 14.2.1. Hemoglobin F
  • 14.2.2. Hemoglobin A2
• 14.3. Market Size (US$ Mn) Forecast By Variant Type, 2025 - 2032
• 14.4. Key Market Attractiveness Analysis

15. Global Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Test Type

Classification of Test Type; highlighting historical trends, current market value, and future projections on the basis of key segments

• 15.1. Introduction/Key Findings
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Test Type, 2019 - 2024
  • 15.2.1. HPLC Test
  • 15.2.2. Hb Electrophoresis
  • 15.2.3. Mass Spectrometry
• 15.3. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
• 15.4. Market Attractiveness Analysis

16. Global Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By End User

• 16.1. Introduction/Key Findings
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By End User, 2019 - 2024
  • 16.2.1. Reference Laboratories
  • 16.2.2. Hospitals
  • 16.2.3. Academic and Medical Institutes
• 16.3. Market Size (US$ Mn) Forecast By End User, 2025 - 2032
• 16.4. Market Attractiveness Analysis

17. Global Adult Hemoglobinopathy Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

• 17.1. Market Value (US$ Mn) Projections
• 17.2. Y-o-Y Growth Analysis
• 17.3. Absolute $ Opportunity
• 17.4. Research Methodology